The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The importance of bridging therapy prior to CAR-T in patients with multiple myeloma
In this video, Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, comments on the importance of bridging therapies for patients with multiple myeloma (MM) who are awaiting CAR T-cell therapy. Dr Hansen notes that decreasing the disease burden before CAR-T administration has been shown to improve patient outcomes, including progression-free survival (PFS). This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I do think that bridging therapy is very important in terms of safely and effectively receiving CAR-T for our patients. As we move CAR-Ts in earlier lines of therapy, we generally have better bridging therapies because our patients are not as exposed to different agents. But then even you know in later lines there’s been some new data either from the German group with some bispecifics, a BCMA and GPRC5D bispecific, and then from the U...
I do think that bridging therapy is very important in terms of safely and effectively receiving CAR-T for our patients. As we move CAR-Ts in earlier lines of therapy, we generally have better bridging therapies because our patients are not as exposed to different agents. But then even you know in later lines there’s been some new data either from the German group with some bispecifics, a BCMA and GPRC5D bispecific, and then from the U.S. Myeloma Immunotherapy Consortium we’ve shown some data with talquetamab bridging in patients who were heavily pre-treated. Both studies look good in terms of outcomes, deepening of responses and on-target off-tumor toxicities generally resolvable and improved after a very short exposure to some of these agents by about a month or so. And there’s been KarMMa-3, CARTITUDE-2, both have subgroup analysis looking at outcomes by decrease in disease burden based on bridging therapy. And essentially what we see is that if we reduce the disease burden by 25% or higher by IMWG criteria, you see that those patients have significantly superior progression-free survival compared to those who had stable or no decrease in disease burden. So I do think overall optimal debulking will allow us to safely and effectively take our patient to CAR T-cell therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
